Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period To End Tomorrow

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period is set to end on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

ARTV has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $7.66 on Tuesday. The business has a 50 day moving average price of $11.27. Artiva Biotherapeutics has a 52 week low of $7.60 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities analysts forecast that Artiva Biotherapeutics will post -4.68 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARTV. State Street Corp acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth approximately $1,337,000. Geode Capital Management LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $4,774,000. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth $42,000. Barclays PLC bought a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $304,000. Finally, Franklin Resources Inc. acquired a new stake in Artiva Biotherapeutics during the third quarter worth about $7,435,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.